Huanaotai Biotech is an innovative vaccine and adjuvant developer focused on novel vaccine and adjuvant product development. The company is building core technology platforms to drive updates and replacement of domestically marketed vaccines. Its stated core platforms include an adjuvant technology platform, a vector technology platform, and an antigen screening technology platform. Huanaotai describes its adjuvant platform as having the potential to be disruptive in the domestic vaccine field. The company announced completion of a RMB 600 million B round.

Total raised

$83M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2024